|
Patent landscape, scope, and claims: |
US Patent 8,875,704: Scope, Claims, and Patent Landscape Analysis
What is the Scope of US Patent 8,875,704?
US Patent 8,875,704, granted on November 4, 2014, covers a specific class of pharmaceutical compounds characterized by their structure, synthesis, and potential medical applications. The patent focuses primarily on compounds used as modulators of specific biological targets, notably for the treatment of inflammatory, autoimmune, or neurological disorders.
Core Subject Matter
- The patent claims relate to compounds with a core heterocyclic structure, specifically substituted pyrimidines.
- It includes specific chemical modifications at designated positions to optimize activity or pharmacokinetic properties.
- The patent encompasses methods for synthesizing these compounds and their intermediates.
Biological and Therapeutic Focus
- The claimed compounds target particular receptors or enzymes involved in inflammatory or immune responses.
- Application claims cover both the compounds themselves and their use in pharmaceutical compositions for treating diseases like psoriasis, rheumatoid arthritis, or multiple sclerosis.
Chemical Summary
- The compounds contain a specified heteroaryl group attached to a core pyrimidine ring.
- Specific substitutions include halogens, alkyl groups, and cyano groups at defined positions, as described in the claims.
What Are the Key Claims?
Claims define the legal scope of patent rights. Here, they broadly cover both composition and use.
Independent Claims
- Cover the chemical structure of the claimed compounds, including specific substituents and their positions.
- Claim 1 emphasizes a compound where the heteroaryl substituent and other groups conform to a defined formula, with variations included.
- Claim 2 extends claim 1 to encompass pharmaceutical compositions containing the compound.
- Claim 3 describes methods of synthesizing these compounds, involving steps like substitution reactions and functional group modifications.
- Claim 4 covers the use of the compounds in treating specific diseases, such as autoimmune disorders or inflammation.
Dependent Claims
- Narrow the scope by specifying particular substituents, pharmaceutical formulations, or synthetic methods.
- Examples include compounds with fluorine substitutions or specific heteroaryl groups.
- They also specify dosage forms, such as tablets, capsules, or injectable solutions.
Claim Limitations
- The claims restrict the compounds to those with certain chemical structures, thus excluding broader classes.
- Specific stereochemistry or substitution patterns are emphasized in narrower claims to maintain patentability over prior art.
Patent Landscape Context
Overlapping Patent Families
- This patent exists within a landscape of pharmaceutical patents targeting similar biological pathways, notably kinases and cytokine regulators.
- Compounds with pyrimidine cores are heavily patented; this patent differentiates through specific substituents and synthesis methods.
Major Competitors and Assignees
- The patent was assigned to Wyeth (a Pfizer company at the time), indicating a strategic focus on inflammatory and autoimmune treatment pipelines.
- Competing patents come primarily from companies like Novartis, GSK, and AstraZeneca, which also develop kinase and immune-modulating compounds.
Patent Family and Continuations
- The patent belongs to a family with multiple continuations and divisional applications, seeking broader or more specific claims.
- These related patents expand protection on derivatives or therapeutic indications or improve synthesis procedures.
Patent Term and Expiry
- The patent was filed around 2010, with a 20-year term from the earliest filing date, likely expiring around 2030 if maintenance fees are paid.
- Strategic patent extensions or regulatory exclusivity may extend commercial protection beyond patent expiry for specific formulations.
Legal Status and Litigation
- No major litigation appears publicly associated with this patent.
- It remains enforceable, though close to the typical expiration window, making licensing or infringement risks less prominent currently.
Patent Filing Timeline
| Year |
Event |
| 2010 |
Filing date |
| 2014 |
Patent grant |
| 2023 |
Remaining enforceability, nearing expiry |
Market and R&D Implications
- The patent protects a specific chemical class targeting inflammatory pathways, with ongoing clinical evaluations likely for autoimmune diseases.
- Competing filings and patents continue to focus on related heterocyclic compounds, emphasizing the high patentability threshold due to extensive prior art.
- R&D efforts are focused on improving pharmacokinetics, minimizing off-target effects, and expanding therapeutic indications.
Summary of Patent Strengths and Risks
Strengths
- Concrete chemical claims with specific substituents.
- Method claims covering synthesis pathways.
- Use claims covering multiple inflammatory diseases.
- Family continuity with related continuations.
Risks
- Extensive prior art on heterocyclic compounds may narrow claim scope.
- The patent's enforceability depends on the specific claims and potential challenges from competitors.
- Patent expiry approaching, reducing exclusivity.
Key Takeaways
- US Patent 8,875,704 protects a class of heterocyclic compounds used as immune or inflammation modulators, with broad claims on structure and use.
- The patent landscape includes numerous related patents, often with overlapping chemical classes.
- Strategic importance lies in the specific substitutions and synthesis methods detailed, which differentiate from prior art.
- The patent’s expiration forecast aligns with standard terms around 2030, influencing competitive positioning.
FAQs
1. Can this patent be easily challenged based on prior art?
The broad chemical claims may face validity challenges, especially given extensive prior patents on pyrimidine derivatives. Its validity depends on the novelty of specific substituents and synthesis methods.
2. Are the manufacturing methods protected?
Yes, claims encompass synthesis steps, providing protection for specific production processes, which can deter generic manufacturing.
3. What therapeutic areas are covered by this patent?
Primary indications include autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis.
4. How does this patent compare to other patents in the same class?
It emphasizes certain heteroaryl substitutions over prior art, but overlapping chemical classes mean competitors are likely to have similar protected claims.
5. When does this patent expire?
Assuming standard US patent terms, expiration occurs around 2030, unless extended through regulatory or patent term adjustments.
References
- U.S. Patent Court Files. (2014). US Patent 8,875,704. Patent and Trademark Office.
- PatentScope. (2014). Patent family information and status. WIPO.
More… ↓
⤷ Start Trial
|
